Philips Interventional Hemodynamic System with Patient Monitor IntelliVue X3 Philips Interventional Hemodynamic System with Patient Monitor IntelliVue X3 patient transit Philips Interventional Hemodynamic System with Patient Monitor IntelliVue X3 cath lab May 14, 2021 Continuous monitoring provides informed, timely clinical decision making and comprehensive, gap-free patient records in the cath lab and beyond Amsterdam, the Netherlands – Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced the integration of its Interventional Hemodynamic System and market-leading portable Patient Monitor IntelliVue X3, providing advanced hemodynamic (blood flow) measurements at the tableside in the cath lab and continuous monitoring of key vital signs throughout the patient journey . The integration provides the opportunity for monitoring during image-guided procedures on the Philips Image Guided Therapy System – Azurion, improving workflow with comprehensive patient records that support timely clinical decision-making during interventional cardiology procedures and beyond. The solution will be introduced at ACC.21, the American College of Cardiology’s 70th Annual Scientific Session and Expo, taking place virtually on May 15-17. Health systems strive to deliver consistent quality patient care while optimizing the interventional room to treat more patients and accelerate care of the critically ill. Uninterrupted patient monitoring, as patients are moved from holding areas to the interventional room and then on to recovery areas, can help to improve clinical decision making and the timely detection of potential adverse events at every stage of the patient journey. Incorporating a 12-lead diagnostic ECG, the monitor removes the need to re-cable the patient or reconnect monitoring, and can help lead to reduced procedural preparation time, enhanced staff efficiency and ultimately an enhanced patient experience. “Philips Interventional Hemodynamic System with Patient Monitor IntelliVue X3 is a unique combination made possible by our strengths in patient monitoring and image-guided therapy,” said Ronald Tabaksblat, General Manager Image Guided Therapy Systems at Philips. “Bringing advanced hemodynamic measurements to the tableside as an integrated part of our Azurion image-guided therapy system, it helps allow clinicians to assess the condition of the patient in real time during an intervention, without leaving the sterile field. It also streamlines workflows, providing continuous monitoring of the patient during every step of their care path, enhancing patient safety and confidence.” The IntelliVue X3 patient monitor can be connected to the patient from anywhere in the hospital, after which it stays with them throughout the interventional procedure, providing continuous monitoring and registration of their vital signs in the IntelliVue IT solution. After connecting the IntelliVue X3 to its docking station at the tableside of the Azurion system, clinical staff can monitor all of the patient’s vital signs including pulse oximetry end-tidal CO2, perform hemodynamic analyses and 12-lead ECG acquisitions, and relay results and waveforms from the lab’s control room to the Azurion tableside display. From the tableside the interventionalists can assess the data using the Azurion tableside Touch Screen Module, allowing them to remain focused on their patients. The system brings the latest physiological techniques to the interventional lab, including iFR (instant wave-Free Ratio) measurements, a hyperemia-free technique unique to Philips that provides valuable functional information regarding the severity of lesions in the coronary arteries. Philips Interventional Hemodynamic System with Patient Monitor IntelliVue X3 integrates with Azurion, the company’s next-generation image-guided therapy system that allows clinicians to easily and confidently perform procedures with a unique user experience, helping to optimize lab performance and provide superior care. At ACC.21 Philips will showcase its solutions for the diagnosis and treatment of Structural Heart Disease, which aim to remove the barriers associated with complex procedures by helping to deliver clinical confidence where it is needed most – at the point of treatment. Philips’ cardiac care solutions help strengthen clinical confidence, build efficiency throughout the care pathway, and enhance care experiences. For more information visit www.philips.com/acc.  Philips Interventional Hemodynamic System with Patient Monitor IntelliVue X3 is available in the majority of markets worldwide. Philips’ continuous patient monitoring solution is available for sale in markets across Europe, Middle East and APAC, with further expansion planned later this year. It is not available for sale in the U.S. For further information, please contact: Mark GrovesPhilips Global Press OfficeTel: +31 631 639 916Email: firstname.lastname@example.org Anna HogrebePhilips Global Press OfficeTel.: +1 416 270 6757Email: email@example.com About Royal Philips Royal Philips (NYSE: PHG, AEX: PHIA) is a leading health technology company focused on improving people's health and well-being, and enabling better outcomes across the health continuum – from healthy living and prevention, to diagnosis, treatment and home care. Philips leverages advanced technology and deep clinical and consumer insights to deliver integrated solutions. Headquartered in the Netherlands, the company is a leader in diagnostic imaging, image-guided therapy, patient monitoring and health informatics, as well as in consumer health and home care. Philips generated 2020 sales of EUR 17.3 billion and employs approximately 77,000 employees with sales and services in more than 100 countries. News about Philips can be found at www.philips.com/newscenter. Attachments Philips Interventional Hemodynamic System with Patient Monitor IntelliVue X3 Philips Interventional Hemodynamic System with Patient Monitor IntelliVue X3 patient transit Philips Interventional Hemodynamic System with Patient Monitor IntelliVue X3 cath lab
If you love big screens, you’ll love what the retailer has to offer
(Bloomberg) -- Raphael Koch, a retailer of medical devices in the small Swiss town of Wil, has been busy for the past two weeks fielding a flurry of phone calls. Most are from Indians or India-based companies looking for oxygen concentrators, with some even wanting as many as 500 at once.But Koch’s Oxymed store barely has any stock left of the little known machines that separate the critical gas from air and assist patients with low blood-oxygen levels. And he isn’t expecting fresh supplies from manufacturers at least until mid-June.“They’re desperate,” he said, referring to the callers he’s been speaking to lately. “They tell me about relatives dying on the streets, that there’s no space in the hospitals and that the few oxygen concentrators that are still available are being sold for up to 10 times the normal price.”After a new coronavirus variant unleashed a brutal wave of infections in India, taking thousands of lives and sending millions to overcrowded and poorly equipped hospitals, demand has shot up for the device. When health-care facilities are running short of oxygen tanks and beds, the portable machine is increasingly becoming a line of defense for those seeking to avert breathing difficulties while recuperating at home.Worst CrisisIndia has reported more than 300,000 daily infections for 22 consecutive days, highlighting the country’s slide into the world’s worst health crisis. One research model is predicting deaths could almost quadruple to 1,018,879 by end-July from the current official count of 258,317. Just as some countries needed ventilators in large quantities last year, India is now desperately seeking oxygen supplies and concentrators.The latest outbreak has seen oxygen requirements at Indian hospitals rise 10-fold, according to Abhinav Mathur, founder of the Million Sparks Foundation, which is part of efforts around Delhi to import the devices and donate them to healthcare facilities. A small part of this surge is being met by the concentrators, he said.To be sure, oxygen concentrators are useful only to those who don’t require intensive care. The machines deliver about five to 10 liters of the gas per minute, typically at about 93% purity, whereas those fighting Covid in hospitals may need as much as 60 liters per minute, which can be met only by liquid-oxygen tanks.Data tracked by the Indian Council of Medical Research between August 2020 and April 2021 show shortness of breath was reported by almost 48% of patients hospitalized this year, compared with about 42% last year. Oxygen utilization jumped to 55% in the second wave, from 41% during the first.Foreign AidIndia needs as many as 200,000 oxygen concentrators to meet the current demand, or five times pre-pandemic levels, Mathur said. Prime Minister Narendra Modi’s government on May 10 said it distributed 6,738 of them from the pool of foreign aid it received in recent weeks, underscoring the inadequacy of supplies and donations trickling in from countries ranging from the U.S. to China and Switzerland.Distraught families are looking to source the gadget -- which could set some back by as much as $1,000, or about half of India’s per capita gross domestic product -- from wherever they can. The cost is an additional burden for some Indians who face shrinking incomes after losing businesses and jobs to lockdowns. A study by Pew Research Center showed an estimated 75 million people slipped into poverty in India since the outbreak began.Some of the biggest manufacturers including Royal Philips NV are stepping in to help. The company has “significantly increased its global production and is making these products available in India to help save more lives,” Philips said in an emailed statement, declining to elaborate.Enough CapacityChinese maker Jiangsu Yuyue Medical Equipment & Supply Co. said in an investor call in April that “orders from India continue to grow.” The Nanjing-based company said its daily production capacity of 4,000 units is sufficient to deliver orders amounting to 18,000 pieces. Shares of the company have jumped 18% in the past month in Shenzhen, compared with the 3% gain in the Shenzhen Stock Exchange Composite Index.Koch’s Oxymed website lists several oxygen concentrators. The EverFlo by Philips, for example, costs 1,550 Swiss francs ($1,715). Other devices have price tags ranging from 1,250 francs to 4,850 francs.Models imported from China may be more affordable at 25,000 rupees ($340), but because of high demand and price gouging, some in Delhi are paying 80,000 rupees for any available piece. Indian budget airline SpiceJet Ltd. said it has airlifted more than 27,000 oxygen concentrators from the U.S., Hong Kong, mainland China and Singapore.Until recently, India’s federal government used to levy an import duty of as much as 20.4% on the oxygenates, but the levies were scrapped temporarily in the first week of May after the red tape prevented life-saving equipment and medicines from reaching the needy.A relief fund set up by the prime minister last year is set to order 150,000 units of an oxygen supply system developed by India’s Defence Research & Development Organisation, the government said Wednesday.Demand for oxygen concentrators are only likely to surge further, said Million Sparks Foundation’s Mathur. Home care, government-run facilities adding more beds and hotels getting converted into Covid care centers will fuel the demand, he said.“The next big worry is that the pandemic is clearly seen moving to semi-urban and rural areas,” he said. “The government should start to plan for improving the availability of oxygen in these areas to be ready to respond.”Meanwhile, in a tiny village about 20 miles east of Zurich, Dino Vivarelli runs MediCur AG, a specialist retailer of all things oxygen, ranging from therapies to air purifiers. He has never done business outside of Switzerland.But after the Indian embassy contacted him about two weeks ago to source large quantities of liquid oxygen, Vivarelli said he’s been getting inquiries from charities and the Indian diaspora in Switzerland and Germany. Until recently, he said he used to be able to order oxygen concentrators by the dozen by email and receive them the next day.“Those days are over,” he said by phone. “It started with a delay of a week. Now we’re already at about a month.”(Updates infections and deaths in fifth paragraph)For more articles like this, please visit us at bloomberg.comSubscribe now to stay ahead with the most trusted business news source.©2021 Bloomberg L.P.